This is an observational, cohort study that will use secondary data to describe thebaseline demographics and clinical characteristics in patients who received EVUSHELD asPrEP against SARS-CoV-2 infection/COVID-19 in Japan.All patients who have a record of administration of EVUSHELD in the database will beincluded in the study. The index date will be defined as the date of first EVUSHELDadministration in the database (Day 0) and the patients will be followed up to 6 monthsafter the index date (Day 1 to 180). The look back period is defined as the 12-monthperiod prior to index date (Day -360 to -1). The exposure of interest will be defined asthe administration of EVUSHELD for use as PrEP against COVID-19. As the result offeasibility assessment, sample size of the study expected to be approximately 280.
This is an observational, cohort study that will use secondary data to describe the
baseline demographics and clinical characteristics in patients who received EVUSHELD as
PrEP against SARS-CoV-2 infection/COVID-19 in Japan.
All patients who have a record of administration of EVUSHELD in the database will be
included in the study. The index date will be defined as the date of first EVUSHELD
administration in the database (Day 0) and the patients will be followed up to 6 months
after the index date (Day 1 to 180). The look back period is defined as the 12-month
period prior to index date (Day -360 to -1). The exposure of interest will be defined as
the administration of EVUSHELD for use as PrEP against COVID-19. As the result of
feasibility assessment, sample size of the study expected to be approximately 280.
Drug: Evusheld
Administration of Evusheld 600 mg
Inclusion Criteria:
- Immunocompromised patients who were administrated EVUSHELD as PrEP and have
administration date of EVUSHELD
- patients aged ≥ 12 years at the index date
Exclusion Criteria:
- Patients who have no medical visit records at any time in the 12 months preceding
the index date
Research Site
Osaka 1853909, Japan
Not Provided